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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 




















• This longitudinal 
cross-sectional study 
suggests that 
vaccinations will be 
required to effect herd 
immunity 
• A longitudinal cross-
sectional study was 
conducted in 100 
communities from the 
13 districts of Wuhan. 
This included 9542 
individuals from 3556 
families 
• Blood samples were 
tested for the 
presence of pan-
immunoglobulins, IgM, 







• A cross-sectional 
sample of the 














• The authors report 




• The authors report 
that their data suggest 
that most individuals 
remain susceptible to 
SARS-CoV-2 infection 
after the first-wave 
epidemic in Wuhan.  






















The Lancet | 
Article 
• Analysis Danish 
population-level 
surveillance data from 
approx.. 4 million people 
(69% of the population) 
who underwent 10.6 
million PCR tests in 2020 
• Estimated protective 
immunity in people <65y 
approx. 80 to 83% 
• Estimated protective 
immunity in people =>65y 
approx. 47% 
• Findings could inform 
vaccination strategies 
including vaccination of 
previously infected 
individuals, especially 
among older people, 
given the observed low 
natural immunity in 






























• A literature review was 
conducted to synthesize 
evidence on the prevalence, 
levels, and durability of 
detectable antibodies after 
SARS-CoV-2 infection and 
whether antibodies to SARS-
CoV-2 confer natural 
immunity. 
• The literature review 
includes 66 observational 
studies. Most studies 
included IgM and IgG most 
frequently, followed by 
neutralising antibodies and 
IgA. 
• The authors conclude that 
from the evidence, most 
adults with RT-PCR 
confirmed SARS-CoV-2 
infection, develop 
antibodies. Levels of IgM 
peak early in the disease 
course and then decline, 
whereas IgG peaks later and 
may remain detectable for at 
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12.03.2021 Therapeutic 
anticoagulation 









• Thrombosis may 
contribute to 
morbidity and 







trial of therapeutic 
anticoagulation 




not improve hospital 
survival or days free 
of organ support 






























• A multicentre 
randomized trial in 
10 academic centres 






(enoxaparin, 1 mg/kg 




(enoxaparin, 40 mg 
daily) (n = 286), with 
modification 
according to body 
weight and creatinine 
clearance. The 
assigned treatments 
were planned to be 
continued until 
completion of 30-day 
follow-up. 
• The primary efficacy 
outcome was a 







mortality within 30 
days. 
• Among 600 
randomized patients, 
562 (93.7%) were 







The primary efficacy 
outcome occurred in 
126 patients (45.7%) 
in the intermediate-
dose group and 126 
patients (44.1%) in 
the standard-dose 
prophylaxis group 
• These results do not 
support the routine 





admitted to the ICU 












• Potential therapeutic 
targets in patients 
with COVID-19 could 
be MX1 
• The study conducted 










902,088 controls with 
European genetic 
ancestry from the 
COVID-19 Host 
Genetics Initiative. 
• Five SNPs within 
TMPRSS2/MX1 
locus (chr.21) are 
associated with 
severe COVID-19. 
• The minor alleles of 
the five SNPs 
correlated with high 
level of MX1 
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• Multicentre, double-blind, 
randomized, controlled 
trial in South Africa was 
conducted to assess the 
safety and efficacy of the 
ChAdOx1 nCoV-19 
vaccine (AZD1222) in 
people not infected with 
the human 
immunodeficiency virus 
(HIV) (aged 18-65 years). 
• 2026 HIV-negative adults 
were included; 1010 and 
1011 participants received 
at least one dose of 
placebo or vaccine, 
respectively. 
• In the primary end-point 
analysis, mild-to-moderate 
Covid-19 developed in 23 
of 717 placebo recipients 
(3.2%) and in 19 of 750 
vaccine recipients (2.5%), 
for an efficacy of 21.9% 
(95% confidence interval 
[CI], −49.9 to 59.8) 
• Among the 42 participants 
with Covid-19, 39 cases 
(92.9%) were caused by 
the B.1.351 variant; 
vaccine efficacy against 
this variant, analyzed as a 
secondary end point, was 




















• Data from 140 countries 
explored the death rate 
from COVID-19 and 
coverage rates of BCG 
and measle-containing 
vaccines (MCV). 
• The authors report 
marginal associations 









coverage and COVID-19 
deaths. 
• However the magnitude of 
association reduced once 
adjusted for Healthcare 
Access and Quality Index. 
The authors conclude that 
the differences in health 
metrics may explain 
associations of vaccines 
with COVID-19 deaths. 

















• Account of the Nigerian 
COVID-19 response based 
on co-production of 
evidence between political 
decision-makers, health 
policymakers and 
academics from Nigerian 
and foreign institutions – a 
multidisciplinary group to 
collaborate on issues 
arising in real time 
• Challenges of the co-
production model included 
limited transparency, 
bureaucratic obstacles and 
an overly epidemiological 
focus on direct impacts of 
the disease compared with 
the social and economic 
effects of response 
measures 
• Authors recommend that 
Nigeria should strengthen 
the integration of the 
national response within 
existing health decision 
bodies and implement 
strategies to mitigate the 
social and economic 
impact, particularly on the 
poorest Nigerians 
 
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
March 
2021 




Reclaim the Gains Global Financing Facility | 
Case for Investment 
22.03.2021 AZD1222 US Phase III trial met primary efficacy 
endpoint in preventing COVID-19 at interim 
analysis 
AstraZeneca| Press release 
20.03.2021 First Person: Prepare for the next pandemic, says 
WHO scientist 
United Nations| New 
19.03.2021 Learning from COVID-19 to reimagine tuberculosis 
diagnosis 
The Lancet Microbe | 
Comment 
19.03.2021 Between the high ideals and reality: Managing the 
Covid-19 vaccine nationalism 
European Journal of Risk 
Regulation 
19.03.2021 Covid-19: What do we know about Sputnik V and 
other Russian vaccines? 
The BMJ: Feature 
19.03.2021 COVID-19 Treatment versus Mycobacterial 
Infections: Better Safe than Sorry? 
Cambridge University 
Press: Letter to Editor 
18.03.2021 Key success factors of Mauritius in the fight against 
COVID-19 
BMJ GH | Commentary 
18.03.2021 Nurses at the frontline of public health emergency 
preparedness and response: lessons learned from 
the HIV/AIDS pandemic and emerging infectious 
disease outbreaks 
Personal View (Nurse) 




18.03.2021 12 months of COVID-19 eliminated 12 years of 
progress in the global fight against tuberculosis 
Stop TB | News 
17.03.2021 WHO statement on AstraZeneca COVID-19 
vaccine safety signals 
WHO | News 
17.03.2021 Innovators target vaccines for variants and 
shortages in global South 
Nature biotechnology| News 
article 
17.03.2021 Vaccinating the world against COVID-19: getting 
the delivery right is the greatest challenge 
BMJ GH | Editorial 
17.03.2021 COVID-19 Vaccines vs Variants—Determining 
How Much Immunity Is Enough 
JAMA Network: Medical 
News and perspective 
16.03.2021 Covid vaccine could be rolled out to children by 
autumn 
The BMJ: News 
16.03.2021 Covid-19: WHO says rollout of AstraZeneca 
vaccine should continue, as Europe divides over 
safety 
The BMJ: News 
16.03.2021 Covid-19: EU looks to speed up vaccine rollout  The BMJ: News analysis 
16.03.2021 Summary for Patients: What is the Antibody 
Response and Role in Conferring Natural 
Immunity After SARS-CoV-2 Infection? Rapid, 
Living Practice Points From the American College 
of Physicians (Version 1) 
Annals of Internal Medicine: 
Summary for Patients 
16.03.2021 Report Weighs Toll of COVID-19 on Women in 
Academic Medicine, Other Science and Technical 
Fields 
JAMA Network: News 
   
 
Dashboards & Trackers   












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 

















LSTM Stop TB 
Partnership 








  IDA 












































































Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 





UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
Online courses Varies WHO 
emergencies, now offers 
10 online courses 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 











COVID-19 Open online 
brief with Dr David 
Nabarro 





Online learning 3 hours WHO 
COVID-19: methods for 
detection, prevention, 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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